A 79-year-old woman with hypertension was evaluated 3 hours and 20 minutes after the sudden onset of left-sided weakness which lasted about 15 minutes and was followed by involuntary, coarse, flinging movements of the left extremities (hemiballistic), occurring every few minutes, and facial asymmetry. Brain computed tomography revealed no abnormalities. The patient received intravenous thrombolysis with 0.9 mg/kg of alteplase 4 hours after the symptom onset. Involuntary movements and central facial nerve paresis subsided within 48 hours of the thrombolysis. Magnetic resonance imaging at day 5 revealed restricted diffusion within the right globus pallidus, which was a new ischemic lesion. Thrombolysis should be considered in hemiballism as a...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Alteplase (recombinant tissue plasminogen activator or rt-PA) remains the only approved treatment (a...
Introduction: Cerebrovascular disease often presents with “negative” symptoms such as weakness with ...
Rapidly onset movement disorders after acute stroke not very commonly reported. The most commonly re...
Rapidly onset movement disorders after acute stroke not very commonly reported. The most commonly re...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Diagnostic and interventional percutaneous coronary catheterization is associated with stroke. Many ...
Diagnostic and interventional percutaneous coronary catheterization is associated with stroke. Many ...
SummaryStroke as a cerebral dysfunction is strongly related to obstruction of cerebral perfusion. Th...
Introduction: While the overall incidence of vertebrobasilar dolichoectasia (VBD) is less than 0.05%...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Alteplase (recombinant tissue plasminogen activator or rt-PA) remains the only approved treatment (a...
Introduction: Cerebrovascular disease often presents with “negative” symptoms such as weakness with ...
Rapidly onset movement disorders after acute stroke not very commonly reported. The most commonly re...
Rapidly onset movement disorders after acute stroke not very commonly reported. The most commonly re...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Diagnostic and interventional percutaneous coronary catheterization is associated with stroke. Many ...
Diagnostic and interventional percutaneous coronary catheterization is associated with stroke. Many ...
SummaryStroke as a cerebral dysfunction is strongly related to obstruction of cerebral perfusion. Th...
Introduction: While the overall incidence of vertebrobasilar dolichoectasia (VBD) is less than 0.05%...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Alteplase (recombinant tissue plasminogen activator or rt-PA) remains the only approved treatment (a...